Neoadjuvant chemotherapy for patients with international federation of gynecology and obstetrics stages IB3 and IIA2 cervical cancer: a multicenter prospective trial

Table 3 Characteristics and treatment details of patients insensitive to NACT who died or developed recurrent disease

Patient No.	Age	FIGO stage	Histology	Deep cervical invasion	LVSI	Lymph node status	Risk level	Therapy after surgery	Patterns of disease recurrence	Therapy after recurrence	Time to recurrence (months)	Time to death (months)
P366	47	IB3	SCC	Positive	Negative	Negative	Intermediate	Chemoradiation	Pelvic Cavity	Untreated	4	6
P294	47	IB3	SCC	Positive	Positive	Negative	Intermediate	None	Pelvic Cavity	Untreated	5	8
P133	44	IIA2	SCC	Negative	Negative	Negative	Low	Chemotherapy	Unknown	Unknown	Unknown	12
P137	42	IIA2	SCC	Negative	Negative	Negative	Low	Chemotherapy	Sigmoid Colon	Radiotherapy	9	16
P080	44	IIA2	SCC	Positive	Negative	Negative	Intermediate	Immu+ Chemoradiotherapy	Cervical Stump	Chemoradiation	3	24
P143	51	IB3	SCC	Positive	Negative	Negative	Intermediate	Chemotherapy	Unknown	Unknown	7	25
P219	32	IB3	SCC	Positive	Positive	Negative	Intermediate	Chemoradiation	Uterine Cervix	Radiotherapy	29	29
P053	34	IIA2	SCC	Positive	Negative	Positive	High	Chemoradiation	Retroperitoneal Lymph Node	Chemoradiation	19	45
P241	47	IB3	SCC	Positive	Negative	Negative	Low	Chemotherapy	Bladder	Radiotherapy	7	35, Alive
P167	43	IIA2	SCC	Negative	Negative	Negative	Low	Chemotherapy	Cervical Stump	Reoperation+Immu.	19	52, Alive
P121	39	IIA2	SCC	Positive	Positive	Negative	Intermediate	Chemotherapy	Cervical Stump	Radiotherapy	20	39, Alive
P373	54	IB3	SCC	Positive	Negative	Negative	Low	Chemotherapy	Pelvic Cavity	Radiotherapy	24	59, Alive
P292	46	IIA2	SCC	Negative	Negative	Negative	Low	Chemotherapy	para-aortic lymph nodes	NA	36	36, Alive
P276	46	IIA2	SCC	NA	NA	NA	NA	NA	Cervix, liver, and lung	Unknown	15	23

Patient No.276 received concurrent chemoradiotherapy after neoadjuvant chemotherapy, and had no surgically pathological results. For Patient 292, recurrence was found in the last follow-up (2021–11), so the treatment options and long-term prognosis after recurrence were not available at the time of writing
Abbreviations: FIGO International Federation of Gynecology and Obstetrics, LVSI Lymph vascular space invasion, SCC Squamous cell carcinoma, AC Adenocarcinoma, NA Not available, Immu Immunotherapy

ISSN: 1471-2407